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Abstract
Background: MicroRNA (miRNA) expression profiles have been described in pancreatic ductal adenocarcinoma (PDAC), but
these have not been compared with pre-malignant pancreatic tumors. We wished to compare the miRNA expression signatures
in pancreatic benign cystic tumors (BCT) of low and highmalignant potentialwith PDAC, in order to identify miRNAs deregulated
during PDAC development. The mechanistic consequences of miRNA dysregulation were further evaluated.
Methods: Tissue samples were obtained at a tertiary pancreatic unit from individuals with BCT and PDAC. MiRNA profiling
was performed using a custom microarray and results were validated using RT-qPCR prior to evaluation of miRNA targets.
Results: Widespread miRNA down-regulation was observed in PDAC compared to low malignant potential BCT. We show
that amongst those miRNAs down-regulated, miR-16, miR-126 and let-7d regulate known PDAC oncogenes (targeting BCL2,
CRK and KRAS respectively). Notably, miR-126 also directly targets the KRAS transcript at a ‘‘seedless’’ binding site within its
39UTR. In clinical specimens, miR-126 was strongly down-regulated in PDAC tissues, with an associated elevation in KRAS
and CRK proteins. Furthermore, miR-21, a known oncogenic miRNA in pancreatic and other cancers, was not elevated in
PDAC compared to serous microcystic adenoma (SMCA), but in both groups it was up-regulated compared to normal
pancreas, implicating early up-regulation during malignant change.
Conclusions: Expression profiling revealed 21 miRNAs down-regulated in PDAC compared to SMCA, the most benign lesion
that rarely progresses to invasive carcinoma. It appears that miR-21 up-regulation is an early event in the transformation
from normal pancreatic tissue. MiRNA expression has the potential to distinguish PDAC from normal pancreas and BCT.
Mechanistically the down-regulation of miR-16, miR-126 and let-7d promotes PDAC transformation by post-transcriptional
up-regulation of crucial PDAC oncogenes. We show that miR-126 is able to directly target KRAS; re-expression has the
potential as a therapeutic strategy against PDAC and other KRAS-driven cancers.
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Introduction
Pancreatic cancer is the 4
th commonest cause of cancer-related
death accounting for 33,000 deaths per year in the US [1,2,3] and
at least 6,000 deaths per year in the UK [4]. Currently surgical
resection remains the only treatment associated with the potential
for cure [5]. However, most patients have locally advanced or
metastatic disease at presentation and are therefore not surgical
candidates [3,6]; the actual resection rate is less than 10% [7].
Routine imaging techniques such as computed tomography (CT)
or magnetic resonance imaging (MRI) are not sensitive enough to
detect pancreatic cancer at an early stage [2]. In addition, patients
continue to be diagnosed with advanced disease because currently
there are no tumor markers that allow reliable screening at a
potentially curable stage.
Cystic lesions of the pancreas can be either inflammatory or
neoplastic [8,9]. The epithelial benign cystic tumors (BCT) of the
pancreas have the potential to transform into invasive pancreatic
ductal adenocarcinoma (PDAC) (Figure S1). Clinical differentia-
tion between low and high-risk pre-malignant BCT can be difficult
and the consequences of missing the chance for a curative
procedure in patients who are suitable for pancreatic surgical
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mucinous and mucinous variants: serous microcystic adenomas
(SMCA), which are non-mucinous tumors, have a very low-
malignant potential (,2%) and very rarely progress to PDAC
[10]; intraductal papillary mucinous neoplasms (IPMN) are
mucinous tumors that are connected to the native pancreatic
ducts (main or side-branch) [11]; whilst the mucinous cystic
neoplasms (MCN) are separate from the ductal system [11,12].
Main branch IPMN lesions carry the highest malignant potential,
ranging between 57 to 92% and side-branch IPMN between 6 to
46% [12,13]. MCNs have a high-malignant potential ranging
from 6 to 36% [14,15]. Out of the BCT, the most often en-
countered are the SMCA (32%–39%), MCNs (10%–45%), and
IPMNs (21%–33%) [16]. The latter have more potential to give
rise to in situ or invasive PDAC, via an adenoma-carcinoma
sequence [3,5,14]. Invasive malignancy arising on the background
of an IPMN is termed Carcinoma-Ex-IPMN (CEI) and is more
common in main pancreatic duct IPMN [12,15,17]. A correct
preoperative diagnosis and evaluation of pancreatic BCT is crucial
for clinical decision-making to sieve out those tumors that are
already malignant or have a high-risk of malignant potential for
which urgent surgical intervention is required [17].
MiRNAs are a recently recognized class of non-coding short
RNAs from 17 to 25 nucleotides in length that play a role in post-
transcriptional gene regulation [18]. Expression profiles of human
miRNAs have demonstrated that many miRNAs are deregulated
in cancer and these profiles will help further establish molecular
diagnosis, prognosis and therapy. Several studies have demon-
strated a different miRNA expression profile in PDAC compared
to normal tissues [2,19,20]. However, the profiles of miRNA
production in PDAC precursor lesions remain largely unknown.
In this report, miRNA expression signatures in low and high-
risk pre-malignant pancreatic BCT were investigated. Further-
more, the role of oncogene targeting miRNAs in the regulation of
malignant transformation from BCT was assessed and KRAS was
identified as a direct target of miR-126. Ultimately, identification of
miRNA markers for the clinical differentiation of these pre-
malignant BCT would allow for early surgical resection to improve
outcomes.
Methods
Tissue samples
Analysis of miRNAs in historical stored formalin-fixed paraffin
embedded (FFPE) and fresh surgical specimens was approved by a
UK national research ethics committee (London; 09/H0722/77)
and by Imperial College Healthcare NHS Trust. Following written
informed consent, specimens were obtained from 58 individuals
who underwent pancreatic resection for a cystic tumor or known
PDAC between May 1999 and November 2010 at the Hammer-
smith Hospital, London, UK. During this period, 4 FFPE and 9
fresh samples of normal pancreas were also collected from
pancreatic resection following trauma. After macroscopic exam-
ination, 10 mm thick sections were obtained from the paraffin
blocks for the FFPE tumor samples (n=43) as in previous studies
[19,21,22]. For the FFPE microarray there were: SMCA (n=7),
MCN (n=6), IPMN (n=7), CEI (n=9) and PDAC (n=14). Our
histopathologist removed any adjacent normal acinar or adipose
tissue with a scalpel. In addition, several sections (3 to 5) were
taken from each block in order to ensure that a representative
sample was obtained. Fresh tissue samples (n=24; normal
pancreas n=9, PDAC n=15) collected at surgery were immedi-
ately placed in RNALater RNA Stabilization Reagent solution
(Qiagen, Hilden, Germany) and stored at room temperature for 2–
3 hours before being frozen at 280uC. The immunohistochemical
analysis was performed on FFPE samples: normal pancreas n=12,
PDAC n=12 and SMCA n=12 (an additional 5 cases of SMCA
were available at this time). Further detailed clinicopathological
information about the patients is provided in Table S1.
Cell culture and transfection
PANC-1 and MIA PaCa-2 pancreatic cells were purchased
from the European Collection of Cell Cultures (ECACC). Both
were maintained in 50% DMEM and 50% RPMI supplemented
with 10% FCS, 1% penicillin/streptomycin, and 1% glutamine.
When the cells were ready for transfection, they were plated in 6
well plate the day before and then transfected with precursor
miRNA (pre-miR) or miRNA inhibitor (anti-miR) (Applied
Biosystems, Cheshire, UK) for 48 hours using HiPerFect Trans-
fection Reagent (Qiagen, Hilden, Germany) before lysis, RNA and
protein extraction.
RNA Isolation
FFPE samples were deparaffinized with xylene and total RNA
was collected using the miRNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. Fresh
tissue stored in RNALater was crushed in liquid nitrogen and
subsequent powder lysed in Trizol Reagent (Invitrogen, Paisley,
UK), followed by RNA isolation according to the manufacturer’s
instructions.
miRNA Microarray
The microarray we used is applicable and has been validated for
FFPE samples [23]. Total RNA was extracted (as mentioned
previously) and the samples were analyzed with the Geniom
Realtime Analyzer (GRTA) using the Geniom Biochip MPEA
Homo sapiens (both by febit biomed gmbh, Germany).
The probes on the biochip are designed as the reverse
complements of all major mature human miRNAs (866 miRNAs)
as published in the Sanger miRBase version 13.0 (March 2009)
[24,25]. The probes are synthesized with 7 intra-array replicates
for each miRNA to increase the statistical confidence and to
compensate for potential positional effects. This microarray
combined with the fully automated GRTA platform allows
for measuring miRNA signatures and ensures a high degree of
reproducibility [26]. Samples were labeled by microfluidic-based
enzymatic on-chip labeling of miRNAs (MPEA) [27]. Following
hybridization for 16 hours at 42uC, the biochip was washed
automatically and a program for signal enhancement was processed
with the GRTA. Resulting detection pictures were evaluated using
the Geniom Wizard Software (febit biomed gmbh, Germany).
We have deposited the raw data at GEO under accession
number GSE29352, we can confirm all details are MIAME
compliant.
RT-qPCR
A selection of miRNAs were chosen for validation based on
statistical significant high levels of logarithmized fold change seen
on the microarray, as well as their known potential roles in
tumorigenesis. Extracted total RNA was used to perform RT-
qPCR using Taqman mature miRNA primers and probes
(Applied Biosystems, Cheshire, UK). Briefly, RNA was reverse
transcribed followed by qPCR on a 7900 HT Fast Real-Time
PCR System (both by Applied Biosystems, Cheshire, UK).
Duplicate samples and endogenous controls (U6, U47 and miR-
191) were used throughout. Expression levels of each miRNA were
evaluated using the comparative threshold cycle (Ct) method as
MiRNAs in Benign vs. Malignant Pancreatic Tumors
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2DCt). The relative expression levels of
each miRNA were calculated between tissue types.
For gene expression analysis, total RNA was reverse transcribed
using Superscript III Reverse Transcriptase (Invitrogen, Paisley,
UK) and cDNA transcripts were amplified by qPCR using SYBR
Green (Applied Biosystems, Cheshire, UK). Triplicate samples
were used and levels were normalized to GAPDH using primers
described in Castellano et al [18]. KRAS primer sequences were
from Kent et al [28].
Luciferase Reporter Assay
For KRAS 39UTRs reporter construction, complementary
oligonucleotides (Sigma Aldrich Ltd., Dorset, UK) containing
the miR-126 recognition elements (MRE) plus 10 nucleotides on
each side were annealed and successively cloned into the Mlu1 and
HindIII sites of the multiple cloning site (MCS) of pMIR-
REPORT Firefly Luciferase vector (Applied Biosystems, Cheshire,
UK). KRAS 39-UTR containing two wild-type (named KRA-
S_A_WT and KRAS_B_WT) and two mutated (named KRA-
S_A_MUT and KRAS_B_MUT) miR-126 binding sites were used
to produce the constructs. The sequences of all primers used for
plasmid construction are reported in Table S2.
MIA PaCa-2 cells were seeded onto 24-well plates (10610
5 cells
per well) the day before transfections were performed. Cells (80%
confluent) were co-transfected with pRL-TK luciferase reporters
(50 ng/well), pMIR-REPORT firefly luciferase (150 ng/well), and
pre-miR-126 (100 nmol/L) using Lipofectamine 2000 (Invitrogen,
Paisley, UK). After 48 hours the cells were lysed using a passive
lysis buffer (Promega, Southampton, UK) and the firefly and
Renilla luciferase luminescence signals were measured using the
Dual-Glo Luciferase Assay System (Promega, Southampton, UK).
Western Blotting
Whole cell lysates were prepared in Nonidet P-40 lysis buffer
[50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 10% (vol/vol)
glycerol, 1% Nonidet P-40, 5 mM DTT (DTT), 1 mM EDTA,
1 mM EGTA, 50 mM leupeptin, and 30 mg/mL aprotinin].
Lysates were subjected to SDS/PAGE and blotted on a Hybond
C super nitrocellulose membrane (GE Healthcare, Bucks, UK).
The intensity of bands was quantified using Image J software
(National Institutes of Health). We used BCL2 (ab692) (Abcam
Plc., Cambridge, UK), CRK (610035) (BD Ltd., Oxford, UK),
KRAS (sc-30) and GAPDH (sc-137179) (Santa-Cruz Biotechnol-
ogy Inc., Santa-Cruz, USA) monoclonal mouse antibodies.
Immunohistochemistry
Sections (4 mm) from FFPE blocks were prepared for immuno-
histochemical examination. After deparaffinisation and rehydra-
tion, antigen retrieval was performed by boiling in 10 mmol/l of
citrate buffer (pH 6.0) for 10 min. After inhibition of endogenous
peroxidase activity for 30 min with methanol containing 0.3%
H2O2, the sections were blocked with 2% BSA in PBS for 30 min
and incubated with antibodies against CRK (as before). The
immune complex was visualised with the Dako REAL EnVision
Detection System, Peroxidase/DAB, Rabbit/Mouse (Dako, Cam-
bridgeshire, UK), according to the manufacturer’s procedure. The
nuclei were counterstained with hematoxylin. Representative
photographs were taken and two pathologists (R.A. and P.C.)
scored the slides for protein expression.
Statistical analysis
The miRNA microarray aimed to detect differential expression
between tissue types. The mean expression values for each miRNA
on the microarray were first background subtracted and normalized
before analysis. Global background subtraction corrects for several
experimental factors that may cause a systematic spatial variability
on a microarray. Following this, the 7 replicate intensity values of
each miRNA were summarized by their median value. Quantile
normalization was then performed across all the different arrays
[29]. These microarray data are presented as the median relative
miRNA expression levels observed and the median logarithmized
fold changes between tissue types.
A hierarchical clustering heatmap was created using the 35
miRNAs with the highest variability in order to separate the data
graphically. This was done because if all the miRNAs were used
then there would be no reliable image, since most are contributing
more background noise than signal. To detect whether partition-
ing was significant, a 363 contingency table consisting of the 3
main groups of tissue type (PDAC, CEI and BCT), was analysed
using Fisher’s Exact test [30]. A P,0.05 was considered a
significant clustering result.
Limma is a test for differential expression analysis of data arising
from microarray experiments. Empirical Bayes and other methods
are used to borrow information across genes, making the analyses
ideal for experiments with a small number of arrays [31,32]. The
resultingP-valueswereadjustedformultipletestingbytheBenjamini-
Hochberg method [33,34]. A log fold change for a deregulated
miRNA with a limma adjusted P,0.05 was considered statistically
significant. Tables S3, S4, S5, and S6 demonstrate the microarray
results for the 30 most deregulated probes (detected by highest
absolute value of logarithmized fold changes) in each tissue
comparison.
The differential miRNA expression between tissues for all RT-
qPCR and Western blotting data was analyzed using the
parametric t-test (unpaired, 1-tailed for validation of the FFPE
samples and unpaired, 2-tailed for fresh tissue samples) with
Graphpad Prism 4.0 (Graphpad Software Inc, San Diego,
California). The immunohistochemistry data was analyzed using
a3 63 contingency table and the Fisher’s Exact test (2-tailed).
Where required, the P-values were adjusted for multiple testing
with the Bonferroni correction.
Results
Microarray expression profiles reveal general miRNA
down-regulation in PDAC compared to low malignant
potential BCT
In order to distinguish the various types of pancreatic tumor,
miRNA expression profiling was performed using total RNA
derived from FFPE tissues of low and high malignant potential
BCT and ductal adenocarcinoma (CEI and PDAC). It has already
been described that PDAC is mainly characterized by miRNA up-
regulation. Bloomston et al. identified 30 miRNAs up-regulated
and 3 down-regulated in PDAC compared to normal pancreatic
tissue [20]. This suggested that miRNA up-regulation represents
an important event for pancreatic cancer progression, but
interestingly comparing the miRNA expression levels between
the low malignant potential BCT and PDAC, general miRNA
down-regulation in cancer was observed (Table S3).
Hierarchical clustering based on the expression of these miRNAs
correctly aggregated benign and PDAC cases. The first cluster
consists of 80% PDAC, 20% CEI and no BCT samples and thus
contains predominantly PDAC samples. The second cluster contains
41% PDAC, 41% BCT and 18% CEI samples and finally the third
cluster contains 14% PDAC, 24% CEI and 62% BCT samples, thus
consists predominantly of BCT samples (Figure 1A). The detected
partitioning and clustering was statistically significant (P=0.034).
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different types of BCT (Tables S3, S4, S5, S6) to observe whether it
would be possible to distinguish between them. Although no
significant differential expression of miRNAs was identified between
theBCTsubgroups (i.e.IPMN vs.MCNorSMCA;IPMNvs.CEI),
21 miRNAs were down-regulated and none were up-regulated in
PDAC compared to SMCA (low malignant potential BCT).
RT-qPCR validates the microarray results
To confirm the microarray results, Taqman RT-qPCR and
normalized miRNA expression levels by snRNA U6, snoRNA U47
and also by miR-191 (as it did not change across tumor type in the
microarray) were used. All of the controls reached the same
statistical significance. Since their deregulation is important for
cancer progression, miR-21 [35–36], miR-126 [37] and miR-16 [38]
were selected for further analysis using RT-qPCR, furthermore
miR-126 and miR-16 have not been well studied in PDAC. RT-
qPCR was performed with the same RNA as in the microarray.
This revealed that although as expected there was no significant
change of miR-21 between the BCT types (Figure 1B), miR-126 and
miR-16 were significantly down-regulated in PDAC compared to
SMCA (low malignant potential BCT) (Figures 1C and D).
MiR-21 is up-regulated in PDAC and SMCA compared to
non-tumor samples
As miR-21 is well described as being up-regulated in PDAC
compared to normal tissues [20], we used normal pancreas to
Figure 1. A subset of miRNAs are down-regulated in PDAC compared to Benign Cystic Tumors (BCT). (A) Hierarchical Clustering Heatmap
was created to detect possible clusters in rows (transcripts) and columns (samples) of the normalized expression matrix. For this analysis we used the3 5
miRNAs with highest overall variability. As the heatmap, with its dendrogram on top and the contingency table at the bottom, shows we detect three
clusters indicated by the solid blue lines. The first cluster consists of 80% PDAC, 20% CEI and no BCT samples and thus contains predominantly PDAC
samples. The second cluster contains 41% PDAC, 41% BCT and 18% CEI samples. Subdividing it into two additional clusters, as indicated by the dashed
bluelines,weseethatthe left part consistspredominantlyofCEI, whilethe rightpart entailsa slightenrichmentforBCTsamples.Finally,thethirdcluster
contains 14% PDAC, 24% CEI and 62% BCT samples, thus consists predominantly of BCT samples (P=0.034). (Red indicates high intensity; green
indicates low intensity; PDAC, Pancreatic Ductal Adenocarcinoma; CEI, Carcinoma-Ex-IPMN; BCT, Benign-Cystic-Tumors). (B) miR-21 (C) miR-126 and (D)
miR-16 were measured using RT-qPCR, performed on the 43 FFPE tissues in order to validate the microarray data. Samples included: SMCA (n=7), MCN
(n=6), IPMN (n=7), and CEI (n=9) and PDAC (n=14). (Results presented as mean6SEM; *** P=0.003, ** P=0.02 and * P=0.05 respectively).
doi:10.1371/journal.pone.0032068.g001
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expression levels of the other selected miRNAs.
RNA from a panel of fresh non-tumorous and PDAC tissues
samples (n=24) was extracted in order to measure miRNA
expression levels by RT-qPCR. We confirmed that miR-21 was
significantly up-regulated in PDAC (P,0.001) compared to normal
pancreas (Figures 2A). Furthermore, no significant changes were
found in the expression levels of miR-126 and miR-16 between fresh
normal pancreas and PDAC tissue (Figures 2B and C), but as
confirmed by RT-qPCR, there was significant down-regulation of
miR-126 and miR-16 between SMCA (low malignant potential
BCT) and PDAC in the FFPE samples (Figures 1C and D).
In order to make a comparison with the FFPE BCT, we
paraffinized some of the normal fresh pancreas samples for RNA
extraction and RT-qPCR validation. Interestingly, in these FFPE
samples we confirmed that miR-21 was up-regulated in PDAC
(n=14), as well as in SMCA (n=7), compared to normal pancreas
(n=4) (Figure 3). This indicates that the expression of miR-21 is an
early event able to increases pancreatic cell proliferation, but not
malignant transformation.
MiR-16, miR-126 and let-7d modulate the expression of
pancreatic cancer oncogenes
The current study has revealed that many of the miRNAs found
to be down-regulated in PDAC compared to SMCA (low
malignant potential BCT) can potentially regulate the expression
of genes which promote malignant transformation. PDAC is
characterized by the deregulation of many proto-oncogenes
among which KRAS, HMGA2, BCL2 and CRK are critical
[39,40,41,42]. The great majority of PDAC cases harbor a gain-
of-function mutation of KRAS that results in the generation of a
constitutively active form [39]. We show that KRAS and BCL2
protein are significantly up-regulated in PDAC patients (Figure
S2A and B). However no significant change was observed at the
mRNA level for KRAS (Figure S2C), suggesting a post-
transcriptional regulation in PDAC that could be mediated by
the miRNA pathway. Moreover, it is already known that KRAS
and HMGA2 are regulated by the let-7 family (family of miRNAs
that we found to be down-regulated in PDAC in our microarray
(Table S3)) in PDAC and other cancers [43]. The levels of KRAS
mRNA have also been found to vary randomly in colorectal
cancer despite consistent up-regulation of KRAS protein expres-
sion [44]. It is also known that miR-16 regulates BCL2 expression
and acts as a tumor suppressor in prostate cancer and chronic
lymphocytic leukemia (CLL) [45,46]. Furthermore, studies have
shown that administration of the precursor to miR-16 into a
murine model of metastatic prostate cancer results in attenuation
of disease progression [47]. Interestingly, it has been shown that
miR-126 directly regulates the expression of CRK in non-small cell
lung carcinoma [48], gastric [49] and breast cancer [50] and one
would expect PDAC to exhibit high expression of CRK if this
oncogene is repressed by miR-126 in pancreas. However, we could
not find any significant difference in CRK protein levels when
comparing normal pancreas and PDAC patient samples (Figure
S2A and B). CRK is a component of the focal adhesion complex
that is involved in integrin signalling and high levels of CRK have
been associated with an aggressive phenotype of carcinomas [50].
We therefore performed immunohistochemical analysis using a
larger sample size, also containing SMCA cases, to stain for CRK
protein directly on the tissue. This identified increased CRK
protein levels in PDAC compared to benign tissues and normal,
indicating a regulatory role of miR-126 in this tumor type.
Representative sections of CRK protein levels in the different
pancreatic tissues can be seen in Figure S3. Analysis using Fisher’s
Figure 2. RT-qPCR of selected miRNAs performed on fresh
tissues. (A) miR-21, (B) miR-126 and (C) miR-16 were measured using
RT-qPCR in order to compare PDAC to normal pancreas for the miRNAs
of interest. MiR-21 is overexpressed in PDAC compared to normal
pancreas tissue (*** P,0.001). MiR-126 and miR-16 expression levels
were not significantly different between PDAC and normal pancreas
tissue. Samples included: normal pancreas (n=9) and PDAC (n=15).
Box and Whiskers indicate median, minimum and maximum.
doi:10.1371/journal.pone.0032068.g002
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staining intensity between PDAC, normal pancreas and SMCA
(P=0.0048).
In order to evaluate whether any of these miRNAs down-
regulate the expression of these oncogenes in PDAC, the miRNAs
were first over-expressed, by transfecting mimics into MIA PaCa-2
and PANC-1 PDAC cell-lines followed by Western blot analysis.
Over-expression of pre-miR-16 down-regulates BCL2 expression
compared to the over-expressed negative control (Figure 4A, 4B
and Figure S4A). Furthermore CRK levels were reduced by pre-
miR-126 transfection (Figure 4A, 4B and Figure S4A) and
surprisingly, KRAS was down-regulated not only by pre-let-7d,
but also by pre-miR-126 in MIA PaCa-2 cells (Figure 4A and 4B).
As it is well documented that the tumour-suppressor let-7 family
regulates KRAS in pancreatic [51,52], lung [53], colon [54] and
breast cancers [55], we concentrated on miR-126 as a novel KRAS
targeting miRNA in PDAC. To this end we performed loss of
function experiments using specific miRNA inhibitors to further
validate this finding. We could demonstrate that in contrast to pre-
miR-126 expression, the down-regulation of miR-126 increases
both KRAS and CRK protein levels (Figure 4C and 4D). Since we
could not see any difference in KRAS mRNA levels using either
pre-miR-126 or anti-miR-126, this indicates that this miRNA
possibly acts on the protein translation step (Figure 4E). The data
herein demonstrate that the down-regulation of multiple miRNAs
in PDAC may contribute to malignant transformation.
MiR-126 regulates KRAS protein translation by
interacting with a ‘‘seedless’’ motif in its 39UTR
We show that over-expression of miR-126 reduces and
conversely its silencing increases KRAS protein levels (Figure 4A,
4B, 4C and 4D). In order to evaluate whether miR-126 directly
regulates KRAS, we performed a bioinformatic search of potential
miR-126 interaction sites in the KRAS mRNA. Using the RNA22
software [56] and the entire KRAS transcript as the input
sequence, we predicted two miR-126 binding sites in the 39UTR
with ‘‘seedless’’ characteristics (Figure 5A). This means that these
interaction sites do not have canonical features of complete
interaction between the 59 seed region of the miRNA [57] and the
39UTR of the gene that has been indicated to be important for the
regulation of the target genes [58]. But instead G-U wobbles were
present in the complementarity between gene and seed miRNA
sequence (Figure 5A). Interestingly, these two regions appeared
evolutionally conserved across species (Figure 5A) and more
importantly it has been recently demonstrated that miRNAs can
regulate gene expression also using ‘‘seedless’’ pairing [58]. For
these reasons we went on to clone the two sites that we termed
KRAS_A_WT and KRAS_B_WT into the 39UTR of pMIR-
REPORT construct along with a mutated version of each (Table
S2) and co-expressed them with the pre-miR-126 in MIA PaCa-2
cells. Over-expression of miR-126 decreased luciferase activity only
when co-expressed with KRAS_A_WT and not the mutated
version (KRAS_A_MUT) (Figure 5B). This indicates that miR-126
directly regulates KRAS at post-transcriptional levels through a
‘‘seedless’’ interaction with its 39UTR.
Discussion
Although the pancreas specific miRNAome and how it is
modified in PDAC has been extensively investigated [59], only a
limited number of studies have looked at miRNA expression in
pancreatic pre-malignant lesions [60,61] indicating an urgent need
for further investigation. Du Rieu et al. examined samples of non-
pathologic pancreatic ducts and microscopic pancreatic intraep-
ithelial neoplasia (PanIN) precursor lesions from a KRAS (G12D)
mouse model and from human FFPE samples adjacent to PDAC.
They showed that miR-21 deregulation occurs in the most
advanced PanIN-3 lesions, before they become invasive PDAC
[60]. Habbe et al. looked at the expression of 12 selected miRNAs
in IPMN compared to normal pancreas and CEI [61]. They found
10 miRNAs significantly up-regulated in IPMN compared to
normal pancreas; of which miR-21 and miR-155 were identified as
possible biomarker candidates for PDAC progression from normal
pancreas to IPMN to adenocarcinoma.
For the first time, we have examined global miRNA expression
in all the epithelial macroscopic pre-malignant pancreatic BCT
(i.e. SMCA, MCN and IPMN), compared to PDAC and CEI, by
microarray to reveal the miRNA-based relationship between these
lesions. Interestingly, with a few exceptions, PDACs tend to cluster
together and remain well separated from the BCT.
There were no significant changes in the miRNA expression
patterns between the various types of BCT, indicating that
miRNA expression changes were not involved in transitions
between the BCT types and more importantly that such transitions
were unlikely to occur in vivo. A widespread miRNA down-
regulation in PDAC was observed compared to SMCA, the most
benign lesion that rarely progress to invasive adenocarcinoma. We
observed that many of the miRNAs down-regulated in PDAC
belong to the same family or cluster. Being that the probes used in
the microarray are randomly located in the platform, we regard
this as validation of our findings. For example, among the
miRNAs that we found to be down-regulated, miR-15a forms a
cluster with miR-16, miR-24 forms a cluster with miR-23a or miR-
27b, miR-29a with miR-29b, miR-143 with miR145 and each cluster
is expressed as a unique primary transcript (Table S3).
It has widely been described that miRNA up-regulation
characterizes PDAC [19,20], whilst cancers are usually charac-
terized by general miRNA down-regulation [62]. We confirm that
miR-21 up-regulation is actually an early event that induces
Figure 3. RT-qPCR confirmed miR-21 overexpression in PDAC
and SMCA compared to normal pancreas. This suggests that miR-
21 overexpression may be an early event in the formation of pancreatic
BCT from normal pancreas. MiR-21 was unable to differentiate PDAC
from SMCA and therefore it may be questionable as a future biomarker
of PDAC. RNA was isolated from FFPE samples for all 3 tissue types.
(Results presented as mean6SEM).
doi:10.1371/journal.pone.0032068.g003
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Dysregulation of proteins involved in miRNA biogenesis in
PDAC, which still need to be characterized, could explain this
event. Among the down-regulated miRNAs in our microarray,
there are many already described as tumor suppressors through
inhibition of known PDAC oncogenes. We show general miR-29
family member down-regulation. Amongst their targets are
DNMT3A and 3B-methyltransferases, whose levels can increase
because of the loss of miR-29, causing CpG island hypermethyla-
tion and cancer [63]. We also show down-regulation of let-7 family
members (let-7f, let-7d, let-7c, let-7a, let-7i) (Table S3), which are
already described as negative regulators of KRAS and HMGA2
oncogenes, whose increased activity is very important during
PDAC progression [53,64]. Furthermore, we show down-regula-
tion of both miR-143 and miR-145, which have recently been
described as being transcriptionally down-regulated by the Ras
signaling pathway, that in turn directly targets KRAS oncogene in
PDAC [28]. This revealed a feed-forward mechanism that
potentiates Ras signaling [28]. This was of interest as it is well
known that KRAS is one of the main genetic promoters of PDAC
[39] and HMGA2 expression levels are associated with the
malignant phenotype in pancreatic exocrine tissue [42], which
could in part be explained by the down-regulation of these
miRNAs. Interestingly, we could see an up-regulation of KRAS
protein, but no change in mRNA levels when comparing normal
tissues to PDAC, indicating that the post-transcriptional regulation
of KRAS in PDAC may be an essential step.
Mutations that result in a constitutively active KRAS are found
in .95% of PDAC and are thought to be a crucial initiating event
for this disease [65]. Furthermore, PDAC continues to be
‘‘addicted’’ to KRAS for epithelial differentiation and cell viability,
indicating that finding new KRAS regulators is an important step
[66]. We show a down-regulation of miR-126 in PDAC, with
increased expression of KRAS. As a result, we evaluated a possible
role for miR-126 in regulating KRAS and found that it is able to
directly regulate KRAS, inhibiting its protein translation by
interacting with a ‘‘seedless’’ site within its 39UTR. This suggests
that its downregulation in PDAC could participate in the
Figure 4. Down-regulated miRNAs allow increased expression of crucial PDAC oncogenes. (A) Western Blots showing expression levels of
BCL2, CRK and KRAS oncogenes in MIA PaCa-2 cells. Transfection was performed for 48 hours with precursor miR-16, miR-126 and let-7d. GAPDH was
used as an endogenous loading control. These are representative blots derived from three biological replicates (nc, negative control). (B)
Densitometric western analysis. Bar diagram of density ratio (protein/GAPDH). Negative control (nc) was set to 1 (*P,0.05; **P,0.01). (C) Western
Blots showing increased expression of CRK and KRAS oncogenes in MIA PaCa-2 cells after silencing of miR-126 using anti-miR (100 nM) transfection
for 48 hours; (D) Densitometric Western analysis. Bar diagram of density ratio (protein/GAPDH). Negative control (nc) was set to 1 (*P,0.05;
**P,0.01). (E) The relative expression of KRAS mRNA after pre-miR-126 or anti-miR-126 was analyzed using RT-qPCR. GAPDH was used as a
housekeeping control. All data are shown as mean6SD.
doi:10.1371/journal.pone.0032068.g004
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MiR-126 expression was in fact down-regulated in PDAC compare
to SMCA (a low malignant potential BCT) and previous studies
have shown that these BCT lesions are devoid of the KRAS
mutation [67,68]. The high malignant potential BCT (i.e. IPMN
and MCN) have been shown to have the mutated KRAS more
frequently [69,70] and we show these lesions had no significant
difference in miR-126 expression when compared to PDAC.
Interestingly, for progression from PanIN to BCT to adenocar-
cinoma these mucinous lesions require KRAS (G12D), followed by
loss of heterozygosity of SMAD4 and mutation of p53 or p16 [71].
As we show miR-126 up-regulation occurs in SMCA, this raises the
possibility of replacement miRNA therapy for those patients with
low miR-126 in their BCT at the time of pre-operative biopsy or
even as adjuvant treatment after surgical resection to prevent
recurrence or control disease.
MiR-16 is often down-regulated in chronic lymphocytic
leukaemia [72], gastric [73], ovarian [74] and prostate cancers
as a tumor suppressor that targets and down-regulates the anti-
apoptotic gene BCL2 [45]. MiR-126 is down-regulated in various
tumors compared to non-cancerous tissues including breast, lung,
stomach, cervix, bladder, and prostate [37]. Recently, miR-126 has
been shown to be a tumor suppressor in gastric cancer as it can
inhibit tumor growth and metastasis in vivo and in vitro. This effect
was partially mediated by down-regulation of CRK [49]. SRC and
CRK-associated substrate phosphorylation is an important
promoter of PDAC anchorage-independence and tumor progres-
sion [41]. SRC is able to repress miR-126 expression levels [50]
and furthermore miR-126 has been described as a suppressor of
proliferation and metastasis in breast cancer [75]. We have
established that miR-16 targets BCL2 and miR-126 targets at least
CRK and KRAS in PDAC cell-lines. As already shown, we did
not observe any significant change in miR-16 and miR-126
expression comparing normal pancreas to PDAC using RT-
qPCR, but did find significant down-regulation of both miRNAs
in PDAC compared to a low malignant potential BCT. Whilst the
down-regulation of miR-16 has not been seen previously in PDAC
compared to normal pancreas [76], the reduction of miR-126 in
PDAC has recently been reported [77]. As both are frequently
down-regulated in several tumor types, their importance in
tumorigenesis is clear.
We could not see miR-21 as up-regulated in PDAC compared to
SMCA. Croce’s group have also examined the oncomiR-21 in more
detail in 80 PDAC specimens and found that it is significantly
overexpressed in PDAC, but that its expression does not correlate
with tumor size, nodal status or T stage [1]. We observed that its
up-regulation from normal tissue is almost certainly a very early
event that occurs in the low malignant potential BCT we studied
and this occurs even earlier than previously described [60,61].
This suggests that miR-21 induces pancreatic cell proliferation, but
it is not sufficient to induce malignant transformation. Since miR-
21 has recently been demonstrated to be up-regulated in PDAC
compared to normal tissue [20] and we show here that it is not
deregulated in PDAC compared to pre-malignant BCT, this
indicates that its up-regulation is likely to be an early event
important for benign neoplasm formation from normal tissue.
The differential diagnosis of pancreatic BCT remains a clinical
challenge. A better understanding of the natural history of these
Figure 5. KRAS is experimentally validated as a direct target of miR-126 in pancreatic cancer cells. (A) Putative miR-126 binding
sequences in the 39-UTR of KRAS mRNA. Two different fragments from the 39-UTR region of KRAS were cloned downstream of the luciferase reporters
and named as wild-type (KRAS_A_WT and KRAS_B_WT). Two mutated versions of the miR-126 binding site were also generated (KRAS_A_MUT and
KRAS_B_MUT); the mutated nucleotides of the miR-126 binding site are underlined. Boxed areas represent conserved complementary nucleotides of
the miR-126 seed sequence in various species (Hsa, human; Ptr, chimpanzee; Mml, rhesus; Mmu, mouse; Laf, elephant; Gga, chicken). *indicates that
KRAS_B_WT is conserved in 16 species. (B) Luciferase reporter assay. Each of the 4 plasmids (150 ng) and a Renilla luciferase reporter (50 ng) were co-
transfected into MIA PaCa-2 cells with precursor miR-126 (100 nM). Luciferase activity was assayed 48 hours after transfection. All experiments were
independently repeated at least three times; the results are presented as mean6SD (**P,0.01).
doi:10.1371/journal.pone.0032068.g005
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transformation. We observed significantly down-regulated miR-
NAs in PDAC compared to low malignant potential BCT, such as
miR-16, miR-126 and let-7d, which could be confirmed by qRT-
PCR and target known PDAC oncogenes such as BCL2, CRK
and KRAS. We thus demonstrate that miRNAs have the potential
to be used to differentiate pancreatic BCT from malignant PDAC
(Figure 6). For the first time we have shown that KRAS is directly
targeted by miR-126 by binding to a ‘‘seedless’’ site in its 39UTR.
As the majority of PDAC are driven by activated KRAS, the re-
expression of this miRNA, along with other miRNAs known to
also negatively regulate this crucial oncogene (i.e. let-7 family, miR-
96 [78] and miR-217 [79]), may provide a therapeutic strategy for
treating this devastating disease.
Limitations
Whilst there are some striking findings from the microarray and
validation, the following should be taken into account. Firstly, the
various pancreatic BCT are very rare (prevalence reported in the
literature as between 0.2–2.6% in the asymptomatic general
population [9]) and the tissues are difficult to obtain as few patients
undergo surgical resection. This is reflected in our small sample
sizes. Thus whilst we conclude that there are no statistically
significant deregulated miRNAs between many of the groups, this
may in fact be a Type II error. Secondly, this is also true of our
validation of miR-16 and miR-126 in PDAC compared to normal
pancreas. Whilst we did not see significant down-regulation for
either of these miRNAs, this may also be a Type II error. Hamada
et al. have recently shown that miR-126 is down-regulated in
PDAC and has tumor suppressive effects by targeting ADAM9,
which enhances cancer cell invasion by modulating tumor-stromal
cell interactions. Re-expression of miR-126 reduced cellular
migration and invasion in PDAC cell lines [77]. It would be
appropriate to undertake further miRNA studies on the high
malignant potential pancreatic lesions and validate candidate
miRNAs in a larger cohort, ideally in the prospective and
multicentric setting.
Supporting Information
Figure S1 Epithelial benign cystic tumors of the pan-
creas. Our study concentrated on the tumors of epithelial origin
in order to identify miRNAs which may be involved in the
development of early neoplasia and pancreatic ductal adenocar-
cinoma (PDAC).
(TIF)
Figure S2 BCL2, CRK and KRAS expression levels in
PDAC and normal pancreatic tissue. (A) Western Blots
Figure 6. Flow chart of miRNA expression profiling in pancreatic BCTs and miRNA target acquisition. (FFPE, formalin-fixed paraffin
embedded tissue; **indicates that RNA could not be isolated from 1 sample; RT- qPCR, quantitative reverse transcription polymerase chain reaction).
doi:10.1371/journal.pone.0032068.g006
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PDAC (n=9) fresh tissue samples compared to normal pancreas
(n=9). (B) Bar chart showing mean relative protein levels of the
Western Blots analyzed by densitometric scanning after normal-
ization to GAPDH (*BCL2 levels in PDAC vs. Normal P=0.03;
**KRAS levels in PDAC vs. Normal P=0.0003). (C) RT-qPCR
performed on the same fresh tissue samples showing KRAS
mRNA levels in PDAC (n=6) compared to normal (n=6) after
normalization to GAPDH.
(TIF)
Figure S3 Immunohistochemical analysis of CRK ex-
pression in pancreatic tissues. Paraffin sections were
analyzed using anti-CRK antibody and counterstained with
hematoxylin. Cytoplasmic staining (brown) was observed in PDAC
and normal pancreas, but not in SMCA. Original photographs
were taken at magnification 206. Staining intensity was measured
as 0 for no expression, 1+ for weak expression and 2+ for moderate
expression. Bar charts indicate the % in each category for each
tissue type. A 363 contingency table was created and analyzed
using the Fisher’s Exact test to reveal a significant difference
between the 3 tissue types (i.e. increased CRK expression in
PDAC.normal pancreas.SMCA; P=0.0048).
(TIF)
Figure S4 Expression levels of BCL2, CRK and KRAS
oncogenes in PANC-1 cells. (A) Western Blots showing protein
levels of BCL2, CRK, KRAS after transfection for 48 hours with
precursor miR-16, miR-126 and let-7d (miRNA mimics). (B) The
relative expression of KRAS mRNA after pre-miR-126 or anti-
miR-126 transfection was analyzed using RT-q PCR and
remained unchanged compared to negative control. GAPDH
was used as a housekeeping control. All data are shown as
mean6SD. (C) Western Blots showing protein levels of CRK and
KRAS after transfection for 48 hours with miRNA inhibitor (anti-
miR-126). GAPDH was used as an endogenous loading control for
all blots. These are representative blots derived from three
biological replicates (nc, negative control).
(TIF)
Table S1 Clinicopathological characteristics of the
patients for each tissue type. MiRNA expression profiling
and validation was performed on 58 pancreatic tumor samples; 43
formalin-fixed paraffin-embedded (FFPE) tumour samples were
analyzed by miRNA microarray and RT-qPCR using Taqman
probes; a further 24 fresh surgical specimens (normal pancreas n=9
and PDAC n=15) were used to validate the results using RT-qPCR.
Samples available for immunohistochemical (IHC) analysis were
normal pancreas n=12, PDAC n=12 and SMCA n=12. Non-
tumorous tissue was obtained during pancreatic trauma surgery. Key:
SMCA, serous microcystic adenoma; MCN, mucinous cystic
neoplasm; PDAC, Pancreatic Adenocarcinoma; IPMN, Intraductal
papillary mucinous neoplasm; CEI, Carcinoma-ex-IPMN; IQR,
interquartile range; *Non-disease related death (cardiac disease), RT-
qPCR, quantitative reverse transcription polymerase chain reaction.
(DOC)
Table S2 Sequences of all primers used for KRAS
luciferase plasmid construction. Red ends indicate sequenc-
es appropriate for the Mlu1 and HindIII restriction enzymes.
Yellow highlighted areas indicate mutated nucleotides.
(DOC)
Table S3 Microarray results for PDAC vs. Serous
Microcystic Adenoma (SMCA). The 30 most deregulated
probes (detected by highest absolute value of logarithmized fold
changes) for PDAC vs. SMCA (low malignant potential tumor).
There is widespread down-regulation of miRNAs in PDAC
(limma adjp indicates the p- value adjusted for multiple testing).
(DOC)
Table S4 Microarray results for PDAC vs. Mucinous
Cystic Neoplasm (MCN). The 30 most deregulated probes
(detected by highest absolute value of logarithmized fold changes)
for PDAC vs. MCN (high malignant potential tumor). No
significant difference in miRNA expression profile was shown
between these 2 tissue types (limma adjp indicates the p-value
adjusted for multiple testing).
(DOC)
Table S5 Microarray results for PDAC vs. Intraductal
Papillary Mucinous Neoplasm (IPMN). The 30 most
deregulated probes (detected by highest absolute value of
logarithmized fold changes) for PDAC vs. IPMN (high malignant
potential tumor). No significant difference in miRNA expression
profile was shown between these 2 tissue types (limma adjp
indicates the p-value adjusted for multiple testing).
(DOC)
Table S6 Microarray results for Carcinoma Ex-IPMN
(CEI) vs. PDAC. The 30 most deregulated probes (detected by
highest absolute value of logarithmized fold changes) for CEI
(carcinoma on background of IPMN lesion) vs. PDAC. No
significant difference in miRNA expression profile was shown
between these 2 tissue types (limma adjp indicates the p-value
adjusted for multiple testing).
(DOC)
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